And the science is only getting more complicated
Based on the dramatic fat reduction (up to 82.4%) and enzyme normalization (70-80%), researchers estimate a high probability of NASH resolution, but this needs confirmation in a dedicated Phase 3 trial with biopsy endpoints (expected 2027-2030)
We are likely to continue to see clinical trials include treatment of adiposity-related diseases as a component of obesity medication investigations
Given the copper pathways implicated, users with pre-existing copper overload, Wilson disease, or severe liver disease may be at increased risk and should avoid use
Additionally, muscles play an essential role in glucose reuptake, insulin sensitivity, strength, mobility, and physical functions